Orthopedics · Medical Literature
Postoperative Delirium After Dexmedetomidine versus Propofol Sedation in Older Adults Undergoing Hip Fracture Surgery with Spinal Anesthesia: A Randomized Controlled Trial.
Abstract
Postoperative delirium is a prevalent complication in elderly surgical patients and is associated with adverse outcomes, including prolonged hospitalization and long-term cognitive impairment. Dexmedetomidine, a highly selective α2-adrenergic receptor agonist, has pharmacological properties that suggest it may reduce the incidence of postoperative delirium. This randomized controlled trial aimed to compare the incidence of postoperative delirium in elderly patients undergoing hip fracture repair under spinal anesthesia with propofol versus dexmedetomidine sedation. This multicenter, randomized, double-blind, parallel-group trial enrolled patients from 12 centers between September 2017 and July 2020. A total of 834 patients scheduled for hip fracture surgery were randomly assigned to receive either dexmedetomidine or propofol for intraoperative sedation. The primary outcome was the incidence of postoperative delirium within 72 hours postoperatively. Secondary outcomes included postoperative pain scores and other complications. The incidence of postoperative delirium was significantly lower in the dexmedetomidine group compared to the propofol group (4.0% vs 7.8%; P = 0.021). Additionally, the dexmedetomidine group exhibited a lower incidence of postoperative headache than the propofol group (3.4% vs 1.7%; P = 0.04). Dexmedetomidine sedation reduces the incidence of postoperative delirium in elderly patients undergoing hip fracture surgery under spinal anesthesia combined with iliac fascia block, compared to propofol sedation. ClinicalTrials.gov, NCT03346226. Principal investigator: Zhanggang Xue. Registered on 14 September 2017.
Clinical relevance
In elderly patients undergoing hip fracture surgery under spinal anesthesia, does intraoperative sedation with dexmedetomidine reduce the incidence of postoperative delirium within 72 hours compared with propofol? __SNAPSHOT__ {"studyDesign":"Multicenter, randomized, double-blind, parallel-group, active-controlled trial","setting":"12 centers in China; enrollment September 2017 – July 2020 (NCT03346226; principal investigator: Zhanggang Xue; corresponding institution: Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai)","sampleSize":"n = 834 (allocation not explicitly reported per arm in abstract; presumed approximately 417 per group given equal randomization — allocation ratio not confirmed in abstract)","population":"Elderly patients scheduled for hip fracture repair under spinal anesthesia. Stringent exclusion criteria applied: patients with dementia, severe cognitive impairment, ASA physical status ≥ 4, and significant comorbidities were excluded, yielding a relatively low-risk subgroup. Age threshold not explicitly stated in the abstract.","intervention":"Dexmedetomidine: loading dose 0.5 μg/kg over 15 minutes, followed by maintenance infusion of 0.5 μg/kg/h until end of surgery; combined with iliac fascia block","comparator":"Propofol intraoperative sedation (dose and titration target not reported in abstract)","primaryOutcome":"Incidence of postoperative delirium within 72 hours postoperatively","followUp":"72 hours postoperatively for the primary outcome; longer-term follow-up not reported","fundingSource":"Not reported"}
Key findings
The incidence of postoperative delirium within 72 hours was statistically significantly lower in the dexmedetomidine group compared with the propofol group (4.0% vs. 7.8%; P = 0.021). The absolute risk reduction (ARR) is 3.8 percentage points (calculated), yielding a number needed to treat (NNT) of approximately 26 (calculated) to prevent one additional case of delirium at 72 hours. Relative risk reduction (RRR) is approximately 49% (calculated). Confidence intervals for the primary outcome were not reported in the abstract. Regarding a secondary outcome of clinical interest, the dexmedetomidine group had a lower incidence of postoperative headache than the propofol group (1.7% vs. 3.4%; P = 0.04) — note: directionality as reported in the abstract indicates dexmedetomidine favored less headache. Postoperative pain scores were listed as secondary outcomes; specific numeric results were not reported in the abstract. No other adverse event rates (e.g., bradycardia, hypotension) were reported in the abstract. Confidence intervals, hazard ratios, and odds ratios for any outcome were not reported in the abstract.
Practice implications
This large multicenter RCT provides confirmatory evidence that intraoperative dexmedetomidine sedation reduces 72-hour postoperative delirium incidence compared with propofol in elderly hip fracture patients undergoing spinal anesthesia — a population less extensively studied in large RCTs to date. The authors themselves acknowledge this direction of effect is not entirely novel, as prior meta-analyses have reported similar findings. Critically, the observed delirium rates (4.0–7.8%) are substantially lower than the 20–25% typically reported in real-world hip fracture populations, which the authors attribute to stringent exclusion criteria (dementia, severe cognitive impairment, ASA ≥ 4, significant comorbidities). This means the findings apply primarily to a lower-risk, cognitively intact, medically optimized elderly subgroup; patients with dementia, severe systemic disease, or high frailty burden — who constitute a large and clinically important portion of hip fracture patients — were not adequately represented. The NNT of approximately 26 (calculated) in this already low-risk population represents a modest absolute benefit. Whether this translates to clinically meaningful reductions in delirium severity, duration, or downstream outcomes (length of stay, institutionalization, mortality, long-term cognitive trajectory) cannot be determined from the abstract alone, as these endpoints were not reported. Delirium was assessed only through 72 hours postoperatively, potentially underestimating true incidence. The co-administration of iliac fascia block in the dexmedetomidine arm is noted in the conclusion but whether both arms received this block equally is not clarified in the abstract, which if unbalanced would be a significant confound. NOTE: This summary is based on the published abstract only; full-text review is required for definitive appraisal. __LIMITATIONS__ Delirium assessed only during the first 72 postoperative hours, likely underestimating true incidence as cases may occur beyond this window.,Stringent exclusion criteria (dementia, severe cognitive impairment, ASA ≥ 4, significant comorbidities) severely limit generalizability to the typical, higher-risk hip fracture population; observed delirium rates (4–7.8%) are far below the 20–25% reported in unselected hip fracture cohorts.,Optimal dexmedetomidine dosing for delirium prevention remains undetermined by this trial; only one dosing regimen was tested.,Confidence intervals for the primary and secondary outcomes are not reported in the abstract, precluding full assessment of precision.,Per-arm allocation, blinding procedures, randomization methods, delirium assessment instrument, and analgesic co-intervention details (e.g., whether iliac fascia block was equally applied across both arms) are not reported in the abstract.,Follow-up beyond 72 hours is not described; long-term cognitive outcomes, delirium duration, severity, and functional recovery were not reported.,Single-country (China), multicenter study: geographic and healthcare-system generalizability to other populations and settings is uncertain.,Funding source is not reported, precluding assessment of potential commercial bias.,The finding is acknowledged by the authors as confirmatory rather than novel; it does not resolve whether the benefit reflects dexmedetomidine's neuroprotection or propofol's relative pro-deliriogenic properties. __BOTTOM_LINE_CATEGORY__ confirmatory __BOTTOM_LINE__ In a carefully selected, low-risk elderly hip fracture population undergoing spinal anesthesia, intraoperative dexmedetomidine sedation reduced 72-hour postoperative delirium incidence compared with propofol (4.0% vs. 7.8%; NNT ≈ 26, calculated), with statistical significance. However, the stringent exclusion of patients with dementia, severe cognitive impairment, and major comorbidities means these results cannot be directly extrapolated to the broader, higher-risk hip fracture population seen in clinical practice. This trial provides useful confirmatory data supporting a preference for dexmedetomidine over propofol when intraoperative sedation is required in cognitively intact elderly hip fracture patients, but does not yet establish sufficient evidence to mandate a change in practice for the full spectrum of patients undergoing this procedure.